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1. Introduction
Clonal plasma cell disorders (PCD) including mostly monoclonal gammopathy of undeter‐
mined significance (MGUS) and multiple myeloma (MM) are characterised by expansion of
abnormal (clonal) plasma cells (PCs) producing monoclonal protein (M-protein, MIG).
Although multiparametric flow cytometry (MFC) allows identification and characterisation of
these neoplastic PCs, this approach is used in routine diagnostics of monoclonal gammopathies
(MGs) complementarily, mostly in unusual cases [4-6]. The technological development of flow
cytometry (FC) in connection with new findings reveal the need for MFC in clinical analysis
of MGs. The main applications of immunophenotypisation in MGs are (1) differential diag‐
nosis, (2) determining the risk of progression in MGUS and asymptomatic MM (aMM), (3)
detection of minimal residual disease in treated patients with MM, and (4) analysis of prog‐
nostic and/or predictive markers. MFC is also very useful also for research analyses focused
on different aspects of B and plasma cell (PC) pathophysiology in term of MG development
as well as in looking for potential myeloma-initiating cells. MFC thus should be included as a
routine assay in monoclonal gammopathy patients. Clinical significance, usefulness and
examples of MFC analyses in MGs are reviewed in this chapter.
2. Flow Cytometry in MGs — Past, present and future
The basic principle of flow cytometry has not changed from the past, it is used for identification
of cell subtypes according to their functional and structural properties. Flow cytometers are
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usually equipped with 2-3 lasers allowing excitation of 6 or more standard fluorochromes and
the term multiparametric and/or polychromatic flow cytometry is used for this approach [7].
The classical immunophenotypisation identifies cells based on their size and granularity/
complexity as well as by the "visualization" of antigen-antibody binding. More than 360
antigens are currently known and commercial monoclonal antibodies conjugated with
different fluorochromes are widely available.
Flow cytometry has been used in diagnostics of MM since 90th years of the 20th century. Mostly
ploidy and proliferative characteristics were analysed, but also the combination of DNA
analysis with cytoplasmic immunoglobulin detection was done [8-10]. Discovery of new
monoclonal antibodies (MoAb) against PCs helped in the development of immunophenotyp‐
isation in MGs [11,12].
It is well known that MFC underestimate the number of PCs when compared to routine
morphological evaluation. However, the sensitivity of MFC is similar to light microscopy,
results obtained using both approaches correlate and the percentage of PCs provided by MFC
is also an independent prognostic factor affecting the overall survival of patients [13]. MFC is
precise in detecting even a small number of PCs and together with analysis of expression of
selected markers, normal and abnormal PCs could be easily discriminated [4]. So MFC is
helpful method for clinical analyses of MGs.
Development of flow cytometry, including powerful instruments with the possibility to
analyze many fluorochromes, availability of new dyes and antibodies, together with accessible
specific software for complex phenotype analysis, require reviewing of current settings in MG
analyses. The shift towards polychromatic analyses should be associated with standardisation
and validation of this method as it is necessary to be consistent in providing analyses and
reporting results. Recently, the European Myeloma Network (EMN) started to use the
Euroflow settings which led to the development of a uniform protocol for the analysis of
biological material of MG cases [14].
3. Development and differentiation of B cells as PC precursors
B cells and PCs as their terminally differentiated stage play an essential role in humoral
immune response. The antigen-dependent phase of B cell differentiation has been extensively
studied for many years. Mature naive B cell (CD19+CD38+/-CD20+CD27-IgM+IgD+) pass from
the circulation into lymph nodes. Recognition of antigen presented on a follicular dendritic
cell together with a costimulatory signal from a specific T lymphocyte causes B cell activation
[15,16]. The activated B cell either migrates to extrafolicullar areas where it differentiates into
a short term plasma cell or moves into a lymphoid follicle to establish a germinal centre (GC)
[17,18]. Massive proliferation of B cell, somatic hypermutation of variable region of Ig chains,
isotype switch and subsequent affinity maturation occur in GC [19,20,18,16]. The aim of these
processes is to generate B cells able to bind the appropriate antigen with a high affinity. Part
of these cells then differentiate into plasmablasts (CD19+CD38++CD20- CD138-CD27+) migrating
into the bone marrow where they mature into long-lived PCs (CD38+CD138+) producing high-
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affinity antibodies. The second group differentiate into long-lived memory B cells
(CD19+CD38+/-CD20+CD27+IgM-/+IgD-/+) [21-23]. Besides these GC derived memory B cells also
exist memory B cells lacking their typical marker CD27 (CD19+CD38+/-CD20+CD27-IgM+/-IgD-)
[24], which likely arise independently from the germinal center reaction [25].
Different maturation stages of B cells give a rise to a variety of B cell lymphoproliferations
including post-germinal centre (post-GC) neoplasms [26-28]. Knowledge of B and PC pheno‐
type is thus important for determination of PCD diagnosis and its discrimination from other
haematological malignancies (Fig 1).
Figure 1. Coexistence of B-CLL and MM. Clone of B-CLL is represented by CD19+CD38-CD138- B cells (turquoise dots)
with cytoplasmic κ expression; clone of myeloma cells (red dots) are typical CD38+CD138+CD56+ PCs with cytoplasmic λ
expression.
4. Identification and immunophenotype of PCs
Syndecan-1 (CD138) is a specific marker of PCs expressed on the surface of both, normal and
malignant PCs from their early stages [29]. Expression of CD138 is usually missing and/or is
not very intensive on circulating PCs and/or plasmablasts in peripheral blood as well as on
immature PCs and/or lymphoplasmacytic cells in bone marrow. Another important marker is
CD38, a non-specific marker, whose bright expression (brighter on normal than on abnormal
PCs) was used to identify PCs for a long time period. Together with CD138 helps in precise
identification of PCs. An important marker for pathological PCs identification is also CD45
which is usually missing on PCs. These surface antigens are still used in analyses, but adding
of other antigens is necessary [30,31].
Mostly terminally differentiated clonal CD38++CD138+CD45- PCs are available in MM bone
marrow. Relative number of PCs (determined by morphology and/or flow cytometry)
corresponds to type of MG, although results could be distorted by dilution of aspirated bone
marrow with peripheral blood. Lower amount of PCs is characteristic for MGUS, aMM
and/or amyloidosis, on the other hand higher PC infiltration occurs in MM. There is no
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possibility to determine PC “abnormality” in low-infiltrated cases without detailed phenotype
study (Fig 2). There are also circulating pathological PCs in peripheral blood of some myeloma
patients, which have usually the same phenotype as bone marrow PCs (mostly CD56-) [32].
Increased absolute (>2x109/l) and/or relative (>20% of leukocytes) count of peripheral PCs
serve as diagnostic criterion of plasma cell leukaemia (PCL). Primary PCL originates de novo,
but secondary PCL occurs in patients with relapsed/refractory myeloma [33]. Primary PCL
is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The
clinical course is aggressive with short remissions and survival duration [34].
Mixture of lymphoplasmacytic cell (LPC) subpopulations with different maturity status
(from B cells CD19+CD20+CD38-CD138- to PCs CD19+CD20+/-CD38+++CD138+) is characteristic
for Waldenström macroglobulinemia (WM), where abnormal LPCs multiply out of control
and produce large amounts of IgM protein [35]. It is supposed that every MM is precede
mostly by non-IgM MGUS, however Waldeström macroglobulinemia and/or B-CLL proba‐
bly arise from IgM MGUS or monoclonal B cell lymphocytosis (MBL) [36,37].
Figure 2. Mixture of polyclonal CD19+ (blue dots) and clonal CD56+/- PCs (violet dots). Heterogeneous expression
of CD56 and nestin, positivity for CD45, negativity for CD27 and CD81 was found in clonal CD38+CD138+ PCs.
Clinically important and necessary antigens allowing discrimination of abnormal from normal
PCs are known and listed in Table 1 [4]. Similar antigens were used in Euroflow settings (Table
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2) [38]. Detailed information about diagnostic and prognostic value of some interesting
markers is mentioned in Table 3. Also other markers should be more and/or less expressed by
PCs, mostly without clinical relevance.
Antigen Normal expression Abnormalexpression
Patients with
abnormal
expression (%)
Requirement for
diagnostics and
monitoring
CD19 Positive (>70%) negative 95% necessary
CD56 Negative (<15%) strongly positive 75% necessary
CD117 Negative (0%) positive 30% recommended
CD20 Negative (0%) positive 30% recommended
CD28 Weak Positivity (<15%) strongly positive 15-45% recommended
CD27 Strong Positivity (100%) weak/negative 40-50% recommended
Table 1. List of surface antigens useful for detection of normal and abnormal CD38+CD138+ PCs in MGs [4].
Tube/
fluorochrom
Pacific
Blue
Pacific
Orange FITC PE
PerCP-
Cy5.5 PE-Cy7 APC APC-H7
1 CD45 CD138 CD38 CD28 CD27 CD19 CD117 CD81
2 CD45 CD138 CD38 CD28 CD56 β2m cIgκ cIgλ
Table 2. EuroFlow PCD classification panel. Tube No.1 is useful for phenotype characterization of PCs and
evaluation markers with potential prognostic significance, tube No.2 is used for detection and discrimination of
normal PCs from aberrant and clonal PCs [38].
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Cluster
Designation
Normal distribution
and functions
Expression in plasma cells
of pre-malignant (MGUS)
and malignant stage of
myeloma
Diagnostic or prognostic
significance
References
CD19 Expressed in all stages
of B cells ranging from
pro-B cells to PCs
MGUS – normal PCs express
CD19 whereas malignant
PCs do not
MM – only negative or dim
CD19 expression on PCs
Facilitate as an identification
marker of malignant and
physiological PCs in
combination with CD56.
Patients with "/>5% of normal
PCs (CD19+CD56-) had better
PFS and OS compared to
patients with ≤ 5% of normal
PCs. Similarly, presence of
"/>5% normal PCs or <95% of
malignant PCs in MGUS and
asymptomatic MM (AMM/
SMM) predicted better PFS
compared to patients with ≤
5% normal PCs or ≥ 95% of
malignant PCS.
[39-41]
CD20 Expressed during
maturation process of B
cells and mostly absent
on PCs
Only few patients express
CD20 on their PCs (< one
third of patients)
Associated with poor
prognosis
[41-43]
CD27 Helps in differentiation
of B cells into PCs
MGUS - consistent
expression on PCs
MM- expression is
heterogeneous and intensity
of expression is lower
compared to MGUS
Lack of CD27 expression
associated with shorter PFS
and OS
[44,45]
CD28 T cell activation MGUS– only very few cases
express CD28
MM– CD28 expressing PC
represents aggressive
phenotype and associates
always with tumour
expansion
Combination of CD28 and
CD117 markers identified
three groups of patients with
different risk. Patients with
CD28-CD117+ PCs (good risk
group) had better PFS and OS
compared to patients with
CD28+CD117- PCs (poor risk)
and patients with CD28-
CD117- or CD28+CD117+ PCs
(intermediate risk)
[46]
CD33 Myeloid and monocytic
cells
A very few MM cases
express CD33 on the surface
of PCs
CD33 expression associated
with poor OS and higher
mortality rate
[47]
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Cluster
Designation
Normal distribution
and functions
Expression in plasma cells
of pre-malignant (MGUS)
and malignant stage of
myeloma
Diagnostic or prognostic
significance
References
CD45 CD45 is a leukocyte
common antigen and
aids in activation and
signaling processes of B
and T cells
MGUS - heterogeneous
distribution of CD45+
normal and CD45- abnormal
PCs in bone marrow
MM - mostly CD45 negative
CD45 expression
demonstrates proliferating
compartment of normal,
reactive and malignant PCs;
immature PCs should be
CD45+ as well
Patients with CD45 positive
expression had better OS than
patients with CD45 negative
expression
[48-50]
CD56 NK and NKT cells One of the most valuable
markers to define the
abnormal phenotype of PCs
in PC proliferative disorders
including myeloma. Loss of
CD56 expression always
associated with aggressive
phenotype of myeloma cells.
Lack of CD56 expression can
be frequently found in
patients with circulating PCs
and extramedullary
myeloma.
Possess substantial diagnostic
value in PC disorders when
combined with CD19 marker.
Patients with CD56 negative
expression on PCs found to
have reduced OS compared to
patients with CD56 positive
expression. Also, CD56
negative myeloma cases
strongly associated with
adverse biological parameters.
[30,51-53]
CD81 Expressed on B cells
including PCs and
regulates CD19
expression
Less than 50% of MM cases
express CD81 on PCs and
expression is heterogeneous
in most of the cases (ranging
from 5%-92%)
Patients with CD81 expression
on myeloma cells had inferior
prognostic outcome (PFS and
OS) compared to patients with
CD81 negative expression
[54]
CD117 Progenitors of myeloid,
erythroid and
megakaryocytic lineage;
mast cells
MGUS- 50% of cases express
CD117
MM- only one third of
myeloma cases express
CD117
CD117 expression on PCs
predicted better outcome in
MM patients. Combination of
CD117 and CD28 markers
delineated MM patients with
different risks; CD117
expression is associated with
an altered maturation of the
myeloid and lymphoid
hematopoietic cell
compartments and favorable
disease features
[46,55-57]
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Cluster
Designation
Normal distribution
and functions
Expression in plasma cells
of pre-malignant (MGUS)
and malignant stage of
myeloma
Diagnostic or prognostic
significance
References
CD138 Plasma cells Both normal and malignant
PCs from MGUS and MM
cases express CD138 but the
expression of CD38 marker
is lower in malignant PCs
Universal marker of PCs and
provides basis to quantify or to
assess disease burden in PC
proliferative disorders
[30]
CD200 Member of
immunoglobulin
superfamily and
expressed on
endothelial cells,
neurons, B cells and a
subset of T cells
MM - more than 70% of
cases do express CD200
MM - more than 70% of cases
do express CD200
Absence of CD200
expression on
myeloma cells
associated with
better PFS
[58,
59]
CD221 (insulin
like growth
factor-1
receptor)
Tyrosine kinase receptor
family, expressed widely
on all types of cells
MM - more than 70% and
85% of medullary and
extramedullary cases
express CD221 on the
surface of PCs, respectively
Patients with CD221
expression had worse
prognosis and CD221+ PCs
were associated with adverse
cytogenetic abnormalities
[55,60]
CD229 Signaling lymphocytic
activation molecules
(SLAM) family member
MM- consistent expression
on PCs
Might represent an attractive
diagnostic and therapeutic
target for MM
[61]
nestin Protein of class VI
intermediate filaments,
marker of multipotent
proliferative precursors
found in some
embryonic and fetal
tissues
MGUS - less than 30%
express nestin; MM - more
than 45% and 80% of
medullary and
extramedullary myeloma
cases express nestin in the
cytoplasma of PCs,
respectively
Patients with nestin expression
should have higher risk to
develop extramedullary type of
MM
[62]
Table 3. Myeloma cell specific antigens and their diagnostic and prognostic values. Abbreviations: PFS - progression
free survival, OS - overall survival
5. Abnormality vs. clonality of PCs
The most useful antigens allowing basic orientation in context of PC normality are CD19 and
CD56 which can allow relatively easy discrimination of immunophenotypically normal
(CD19+CD56-) from immunophenotypically aberrant (CD19-CD56+) PCs [63-65]. As was
verified by cytoplasmic analysis of immunoglobulin light chains kappa and lambda, this
discrimination should be used just for orientation and does not have to correspond to a real
number of polyclonal and clonal PCs, especially in unusual cases and/or time after treatment.
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Thus polychromatic FC (minimum of 6 markers, but usually 8 markers) is required for
sufficient PC analysis and combination of surface and intracellular antigens is necessary for
identification and clonality assessment of PCs [66-68]. Only a limited number of cases requires
more than 8 markers to detect a small clonal subpopulation of PCs on the prevailing back‐
ground of polyclonal PCs. Use of marker with a known aberrant expression on analysed PCs
(CD28, CD117 etc.) could help in precise identification of clonal PCs. Marker CD27 should be
useful as loss of this antigen should reveal clonal PCs (Fig 3). Together with analysis of a
sufficient number of PCs, the sensitivity of polychromatic FC should reach the sensitivity of
the PCR approach [5,67].
6. Clinical application of flow cytometry in MGs
FC should be used not only for assessment of PCs in peripheral blood (PB) and/or bone marrow
(BM), but in simultaneous analysis of 8 markers on a single cell could identify the type of PCs
that has clinical and predictive value.
6.1. Differential diagnostics
Identification and enumeration of PCs is as important as discrimination between normal
polyclonal PCs in reactive plasmocytosis and clonal PCs in plasma cell disorders (MGUS, MM,
PCL, extramedullary plasmocytoma) [4]. It was found that BM of MGUS cases contained a
mixture of polyclonal PCs with normal phenotype and clonal PCs with aberrant phenotype,
on the other hand there is a majority of clonal PCs in MM [63,65]. Presence of more than 5%
normal PCs in BM should be used as a cut-off value for differentiation between MGUS and
MM [40]. Surprisingly there were found symptomatic MM patients with more than 5% normal
PCs in BM, these should be signed as “MGUS-like MM” and have a low incidence of high-risk
cytogenetic abnormalities with a longer progression-free survival and longer overall survival
as well [39]. There are clonal non-myelomatous PCs present in Waldenström macroglobuli‐
nemia (WM) so careful PC analysis should be done in these patients especially when they have
low number of PCs [35]. Discrimination of myelomatous from non-myelomatous PCs then
should help in determination of other lymphoproliferations [28].
6.2. Determination of the progression risk in MGUS and MM
Conventional parameters related to the higher risk of progression of MGUS into MM are
monoclonal Ig level (MIG) > 15 g/l and non-IgG isotype of MIG. Even so, a new parameter is
serum free light chain (FLC) ratio. These parameters were used for risk stratification model
[69]. Simultaneously evolving and non-evolving theory of MGUS type, based on evolutionary
pattern of MIG (increasing vs. stable) was published [70]. Mentioned parameters are important
in patient monitoring for decades, but FC approach based on pathological PCs enumeration
is quicker with a better predictive value [40]. Finding ≥95 % pathological PCs (from all PCs) is
an independent parameter with a predictive value, in term of risk of progression MGUS and/
or a MM into symptomatic form. When compared FC results with a parameter describing
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evolution of monoclonal component, the risk of progression was better described by immu‐
nophenotypisation [71]. Multiparametric FC is thus capable to distinguish patients which need
more frequent monitoring and which need to start treatment earlier than usual. There is still
not any marker allowing discrimination between benign MGUS and its malignant form at this
moment.
6.3. Prognostic markers in MGs
Determination of immunophenotype should be used not only for discrimination of normal
and pathological PCs, but it has also prognostic value. The loss of CD56 (neural cell adhesion
molecule, NCAM) should be joined with extramedullary spread [72]. An association between
the phenotype profile and cytogenetic abnormalities was found. Expression of CD19 and CD28
and/or absence of the CD117 on pathological PCs are joined with significantly shorter time
without progression and overall survival in transplanted patients [46]. Expression of CD28
correlated with t(14;16) and del(17p), on the other hand no presence of CD117 was joined with
t(4;14) and del(13q). The analysis combining both CD28 and CD117 was able to divide patients
into 3 risk groups with different time without progression and overall survival. The correlation
of CD117 expression with hyperdiploidy was found as well [73]. The expression of CD117 on
PCs is associated with changes in production of haematopoietic stem cells from BM, lead to a
decreasing number of neutrophils in PB and the presence of normal PCs in BM [57]. Recently,
a rare MM case was described with PCs phenotype: CD19+CD56-
CD20+CD22+CD28+CD33+CD117+HLA-DR+. Moreover, the cytogenetic analysis of this case
revealed a hyperdiploid karyotype and no rearrangement of the IgH gene or deletion of 13q14
[74]. The very important genetic change in MM is loss of the gene for CD27 which is linked
with clinically aggressive disease, but in about 50% of MM is expression of CD27 preserved
and these patients have better prognosis [44]. Probably the best prognostic information until
now serves a combination of two independent parameters: the presence of high-risk cytoge‐
netics by FISH and persistent minimal residual disease evaluated by multiparameter flow
cytometry at day +100 after autologous transplantation. These two parameters were able to
identify patients in complete remission at risk of early progression [75]. The important thing
is that these two methods are available in most hospitals taking care of patients with haema‐
tological malignancies.
6.4. Minimal residual disease analysis
It is known that conventional parameters (% PCs, MIG level) are not sensitive enough for
analysis of treatment response in MM patients. As FC is applicable up to 80-90% of patients,
this  method is  able  to  reach the sensitivity  of  allelic-specific  oligonucleotide (ASO)-PCR
(sensitivity 10-4 for FC vs. 10-5 for PCR) and is less time and monetary consuming as well.
Hence FC looks as  the optimal  method for  minimal  residual  disease (MRD) assessment
after any treatment [76,77]. The advantage of FC in MRD analysis is the versatility of used
markers  allowing assessment  of  normal  and abnormal  PCs  (CD19/CD56),  removing the
need to know the original phenotype of PCs before treatment. MRD negativity proved by
FC  (detection  <10-4  myeloma  PC  within  all  nucleated  cells)  was  more  informative  then
Multiple Myeloma - A Quick Reflection on the Fast Progress102
positive  immunofixation  (IF)  after  autologous  transplantation  (regarding  to  time  to
progression and overall  survival),  so  FC is  sufficiently  sensitive  method and should be
used for routine MRD analysis [78].
6.4.1 Better definition of complete remission
Using new treatment protocols led The International Myeloma Working Group (IMWG) to re-
view treatment response criteria. There was included also FC analysis in the assessment of
stringent complete response (sCR), more precisely the absence of phenotypically aberrant PCs
in 3000 PC analysed by multiparametric FC (≥ 4 colours) [79]. Criteria of MRD level assessment
are changing nowadays as newer more efficient treatment protocols are available and FC has
technically developed. When used flow cytometry for confirmation of (s)CR, the new term
„immunophenotype remission (iCR)” - a state without presence of any clonal PCs should be
used [79, 80]. The evidence suggests that the 4-colour FC is not sufficiently sensitive for
confirmation of iCR and standardized polychromatic flow cytometry is the best approach (Fig
3).
7. Conclusion
Flow cytometry analysis was performed only in a limited number of subjects with monoclonal
gammopathies in the late 1990’s and early 2000’s. During the past decade and present, many
analyses showed importance of MFC in differential diagnostics and monitoring (management)
of plasma cell diseases. The MFC has developed significantly and with better understanding
of PC pathophysiology is the mandatory diagnostic tool which should be included as a routine
assay in monoclonal gammopathy patients.
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